Recently, the burden on healthcare systems has significantly increased due to the sudden outbreak of the COVID-19 pandemic due to the direct or indirect effects of infection such as cardiovascular complications, thromboembolic complications, neurological complications, cytokine release syndrome leading to acute respiratory distress syndrome (ARDS) and multiple organ failure, and potentially death with case fatality rate (CFR) currently estimated as 6% based on the WHO data as of 04June2020. The overall CFR appears to be less than that reported for severe acute respiratory syndrome coronavirus (SARS) (10%) and Middle East respiratory syndrome (MERS) (37%). Despite the lower CFR, COVID-19 has so far resulted in more deaths than both SARS and MERS combined*. This global health crisis has taken precedence over several other ongoing issues and thus, the focus of worldwide health care and clinical research industry is shifted towards urgently developing a safe and effective therapeutic modality that could be offered to millions at a very nominal cost.
With new technologies, innovative products, and limitless imagination, many different types of cells may be used as part of a therapy or treatment for a variety of rare diseases and in advanced conditions. Cellular therapy is the transplantation of human cells to replace or repair damaged tissue and/or cells to treat an illness or a disorder.
This review article aims to provide a comprehensive information about the ongoing research of cellular therapies in managing COVID-19 related complications. Our team of experts have collated this information which is an excellent read for professionals and researchers.
Stay safe and healthy!
*Ref: https://bestpractice.bmj.com/topics/en-gb/3000168/prognosis